Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
about
Review and management of drug interactions with boceprevir and telaprevirThe role of drug transporters in the kidney: lessons from tenofovirTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?HIV Infection in the Elderly: Arising ChallengesRole of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionDrug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic StudyLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticePrevalence and factors associated with renal dysfunction among HIV-infected patientsImpact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Antiretroviral therapy in the clinicEffects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitorsRenal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineThe New Epidemiology of HIV-Related Kidney Disease.Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, MalawiCo-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialCystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in miceTenofovir-associated renal dysfunction in clinical practice: An observational cohort from western IndiaFanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patientsHigher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.An update on the use of Atripla in the treatment of HIV in the United States.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected ChildrenRenal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific
P2860
Q24628716-7F2BD1EC-48BB-4128-8677-67E554C75A2BQ26866489-9CA06C59-0070-448D-ACD0-0B0269DA1CA4Q26995852-82D0AF75-CA89-42B7-9DDD-1C107754D53EQ28076000-88D9C134-E91E-4169-8146-54C8021578C3Q28533843-AC7AD089-6434-42A8-9139-32EE6861B00FQ28543732-5F690FAC-C1F8-4EDB-9630-C2EFE17F7316Q28550681-5C502219-D5A6-4F12-99A5-1DBF6E4F4AA6Q28554567-2784F6B0-77D0-4FA0-8E1D-4B02C3E70EC9Q30484533-70904097-CCE6-45C4-BE2D-0C5798742C6DQ31028855-C8A8DB13-B031-4E8A-9B14-1D1EAC1EFDECQ31108490-CB5F0618-E1C0-401B-A0FB-1F0BDB75180BQ33775397-22B8F1B8-29AC-4843-9E32-2F3060A94442Q33877347-60C4FAC1-4664-40ED-B510-CE78D08DA498Q33880418-A17667F2-8C9A-43B0-9D71-3A699E32363AQ34126724-F12F5662-4E97-4460-B494-EE0D7788AD15Q34136166-5F1723DE-0440-459E-A6B6-38B0396AB47DQ34250879-7A71CC93-6347-4F7F-B9F2-1B4FD386B1E2Q34307868-B7343163-BAEE-4343-A2E1-832D95C8D0BBQ34358152-FCFEFA2B-42F0-46ED-97C4-6C9F5591EF18Q34475217-8E828D19-357E-4F14-A1FD-A43FCEC81BE0Q34686870-55564BAA-38F2-439A-B25C-0BD0C2BC5F08Q34736194-939FBB12-37C0-4DB8-A91E-C5A830B23318Q34787977-BDD0B2A3-4DC2-482B-AABE-AAA15C733EFAQ34952127-DBD4B0B0-2753-401F-BC3D-A01C9A3C432FQ35071954-0DFE9327-5900-400D-80A5-55EFB7A00DEAQ35102322-FF87D752-8231-46DC-BFD4-FFB743A05878Q35117296-239D1877-82C4-463C-AAF3-0528AED6C60AQ35126728-F8510710-1A0B-47CF-91A6-3302A9E0E99DQ35134488-96081268-8E5B-4C8E-B212-EC046CB141FAQ35186842-AF1CB3EE-D5AF-46DF-B035-DFDEB9329A3FQ35214141-D18D8E93-5258-47A6-BF44-3BBC87DBAA73Q35337952-60466657-F672-48FD-B050-317539047800Q35363649-6528CE9C-FC37-4C40-B20A-6462C3CE6F72Q35557269-235BFFF5-244F-4F10-B380-CBE9B0EB7A64Q35566732-7E952D3C-5884-4C41-813C-8F59A759E94AQ35748339-17C058EE-A5B8-4A27-969D-884698F33B9AQ35908584-B5CFD5B1-5DE9-4BD4-929D-20B74F222A25Q36033710-8F73E480-0002-416A-BA4C-82E666DB568DQ36070335-CF1CC41E-07DC-45EA-8359-16DED234C9D5Q36113151-67E26C78-CBB5-4B95-93CB-03F9B91C8C0D
P2860
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@en
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@nl
type
label
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@en
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@nl
prefLabel
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@en
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@nl
P2093
P2860
P356
P1476
Greater tenofovir-associated r ...... ptase inhibitor-based therapy.
@en
P2093
Brookie Best
California Collaborative Treatment Group 578 Team
Carol Kemper
Catherine Diamond
Mallory Witt
Miguel Goicoechea
Richard Haubrich
Shanshan Liu
Shelly Sun
Sonia Jain
P2860
P304
P356
10.1086/524061
P407
P577
2008-01-01T00:00:00Z